Stati Uniti - inglese - NLM (National Library of Medicine)

tya pharmaceuticals - tuberculin purified protein derivative (unii: i7l8fkn87j) (tuberculin purified protein derivative - unii:i7l8fkn87j) - tuberculin purified protein derivative 5 [iu] in 0.1 ml - tuberculin ppd is indicated as an aid in the detection of infection with . the standard tuberculin test employs the intradermal (mantoux) test using a 5 tu dose of tuberculin ppd. the 0.1 ml test dose of aplisol (tuberculin ppd, diluted) is equivalent to the 5 tu dose which has been clinically utilized and standardized with ppd-s. tuberculin skin testing is not contraindicated for persons who have been vaccinated with bcg and the skin-test results of such persons are used to support or exclude the diagnosis of infections. hiv infection is a strong risk factor for the development of tb disease in persons having tb infection. all hiv-infected persons should receive a ppd-tuberculin skin test. mycobacterium tuberculosis 7 m. tuberculosis 4 3 aplisol is contraindicated in patients with known hypersensitivity or allergy to aplisol or any of its components. aplisol should not be administered to persons who have previously experienced a severe reaction (e.g., vesiculation, ulceration, or

Stati Uniti - inglese - NLM (National Library of Medicine)

remedyrepack inc. - tuberculin purified protein derivative (unii: i7l8fkn87j) (tuberculin purified protein derivative - unii:i7l8fkn87j) - tuberculin purified protein derivative 5 [iu] in 0.1 ml

Stati Uniti - inglese - NLM (National Library of Medicine)

merck sharp & dohme corp. - hepatitis b virus subtype adw hbsag surface protein antigen (unii: xl4hlc6jh6) (hepatitis b virus subtype adw hbsag surface protein antigen - unii:xl4hlc6jh6) - hepatitis b virus subtype adw hbsag surface protein antigen 1 g in 1 g

Stati Uniti - inglese - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - neisseria meningitidis group b nhba fusion protein antigen (unii: 28e911y7ae) (neisseria meningitidis group b nhba fusion protein antigen - unii:28e911y7ae), neisseria meningitidis group b fhbp fusion protein antigen (unii: 25db599g64) (neisseria meningitidis group b fhbp fusion protein antigen - unii:25db599g64), neisseria meningitidis group b nada protein antigen (unii: 1s25r442rs) (neisseria meningitidis group b nada protein antigen - unii:1s25r442rs), neisseria meningitidis group b strain nz98/254 outer membrane vesicle antigen (unii: 91523m4s24) (neisseria meningitidis group b strain nz98/254 outer membrane vesicle antigen - unii:91523m4s24) - neisseria meningitidis serogroup b nhba fusion protein antigen 50 ug in 0.5 ml - bexsero is a vaccine indicated for active immunization to prevent invasive disease caused by neisseria meningitidis serogroup b. bexsero is approved for use in individuals aged 10 through 25 years. approval of bexsero is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup b strains representative of prevalent strains in the united states. the effectiveness of bexsero against diverse serogroup b strains has not been confirmed. hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of bexsero [see description (11)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. there are no adequate and well-controlled studies of bexsero in pregnant women in the u.s. available human data on bexsero administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. a developmental toxicity study was performed in female rabbits administered bexsero prior to mating and during gestation. the dose was 0.5 ml at each occasion (a single human dose is 0.5 ml). this study revealed no adverse effects on fetal or pre-weaning development due to bexsero (see data) . data animal data: in a developmental toxicity study, female rabbits were administered bexsero by intramuscular injection on days 29, 15, and 1 prior to mating and on gestation days 7 and 20. the total dose was 0.5 ml at each occasion (a single human dose is 0.5 ml). no adverse effects on pre-weaning development up to postnatal day 29 were observed. there were no fetal malformations or variations observed. risk summary it is not known whether the vaccine components of bexsero are excreted in human milk. available data are not sufficient to assess the effects of bexsero on the breastfed infant or on milk production/excretion. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for bexsero and any potential adverse effects on the breastfed child from bexsero or from the underlying maternal condition. for preventive vaccines, the underlying maternal condition is susceptibility to disease prevented by the vaccine. safety and effectiveness of bexsero have not been established in children younger than 10 years. safety and effectiveness of bexsero have not been established in adults older than 65 years.

Stati Uniti - inglese - NLM (National Library of Medicine)

natural health supply - tuberculin purified protein derivative (unii: i7l8fkn87j) (tuberculin purified protein derivative - unii:i7l8fkn87j) - tuberculin purified protein derivative 30 [hp_c] - indications: to be used for acute, self-limiting conditions according to standard homeopathic indications.

Stati Uniti - inglese - NLM (National Library of Medicine)

a-s medication solutions - tuberculin purified protein derivative (unii: i7l8fkn87j) (tuberculin purified protein derivative - unii:i7l8fkn87j) - tuberculin purified protein derivative 5 [iu] in 0.1 ml - tuberculin ppd is indicated as an aid in the detection of infection with mycobacterium tuberculosis . the standard tuberculin test employs the intradermal (mantoux) test using a 5 tu dose of tuberculin ppd.7 the 0.1 ml test dose of aplisol (tuberculin ppd, diluted) is equivalent to the 5 tu dose which has been clinically utilized and standardized with ppd-s. tuberculin skin testing is not contraindicated for persons who have been vaccinated with bcg and the skin-test results of such persons are used to support or exclude the diagnosis of m. tuberculosis infections.4 hiv infection is a strong risk factor for the development of tb disease in persons having tb infection. all hiv-infected persons should receive a ppd-tuberculin skin test.3 aplisol is contraindicated in patients with known hypersensitivity or allergy to aplisol or any of its components. aplisol should not be administered to persons who have previously experienced a severe reaction (e.g., vesiculation, ulceration, or necrosis) because of the sev

Malta - inglese - Medicines Authority

medical logistics ltd no 8, ivo muscat azzopardi street, st julians stj 1905, malta - tuberculin purified, protein derivative - solution for injection - tuberculin purified protein derivative 5tu - diagnostic agents

Malta - inglese - Medicines Authority

nm pharma limited 3/4, cantrija complex triq it-targa, il-maghtab naxxar nxr 6613 , malta - tuberculin purified, protein derivative - solution for injection - tuberculin purified protein derivative 5tu - diagnostic agents

Filippine - inglese - FDA (Food And Drug Administration)

zoetis philippines, inc.; distributor: zoetis philippines, inc. - gonadotropin releasing factor (gnrf) analogue protein conjugate (vet.) - solution for injection (sc) - formulation: each 2 ml (dose) contains: gonadotropin releasing factor (gnrf) analogue-protein conjugate ... (gnrf conjugated to diphtheria toxoid synthetic peptide analogue) 2300 ug.

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

grifols deutschland gmbh - alpha-1-proteinase inhibitor - powder and solvent for solution for infusion - 1000 milligram(s) - proteinase inhibitors; alfa1 antitrypsin